The largest study to date of the most common form of testicular cancer has uncovered a possible link between disease risk and variations in the genes controlling cell shape and movement. The study reveals new insights into how rare genetic variants may contribute to susceptibility – laying… Read More
Data from the Friends of Cancer Research’s (Friends’) ctMoniTR Project, recently published in Clinical Cancer Research (CCR), demonstrate a strong association between changes in levels of circulating tumour DNA (ctDNA) and treatment outcomes. This offers the potential for integration of ctDNA analysis in therapeutic development programmes, and clinical cancer… Read More
This is the latest episode of the free DDW narrated podcast, titled “Getting to know key drug discovery leaders”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Sitting down with… Neil Dhawan”, “Meet the researcher: Giusy Di Conza, iOnctura”… Read More
Scientists at The Institute of Cancer Research, London, have identified a gene that affects how ovarian clear cell carcinoma (OCCC) could respond to a new class of drug called ATR inhibitors. In clinical trials, ATR inhibitors have demonstrated efficacy as a treatment for various types of cancer,… Read More
New research has provided insight into the biological mechanisms that may contribute to poor outcomes in some cases of neuroblastoma. A high-risk form of the disease that is difficult to treat is often associated with mutations in the ATRX gene, which controls the expression of multiple sections… Read More
This is the latest episode of the free DDW narrated podcast, titled “The revolutionary impact of understanding genomics”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Open science, genomics, and the quiet revolution in our approach to pharma” and “… Read More
A team of international researchers have secured £1.5 ($1.9) million funding from Cancer Research UK (CRUK) to study the genetic secrets of childhood cancer neuroblastoma. The project will be led by scientists at the University of Sheffield, alongside colleagues from The Institute of Cancer Research (ICR), Kings… Read More
PrecisionLife and Metrodora Foundation have successfully reproduced the genetic risk factors associated with long Covid across US and UK patient populations with diverse ancestries. The landmark study represents a significant step forward in understanding the genetic underpinnings of long Covid and offers… Read More
The largest genetic study to date into long-term health conditions of later life has identified opportunities for new ways to treat multiple overlapping conditions. Currently, nine million people in the UK live with two or more long-term conditions at the same time (multimorbidity). Their treatment accounts for… Read More
DDW Editor Reece Armstrong speaks to Cassie Gorsuch, Vice President, Gene Therapy, at Precision BioSciences about limitations in treating hepatitis B (HBV) and the company’s recent clinical trial application (CTA) approval in Moldova for its lead candidate PBGENE-HBV. RA: What are the limitations of current standard-of-care treatments for HBV? CG:… Read More
Tina Rogers, Senior Technical Director, Toxicology at WuXi AppTec, discusses the ethical and safety challenges of developing antisense oligonucleotides. Antisense oligonucleotides (ASOs) have emerged as a promising class of therapeutics, offering unique mechanisms to target and silence disease-causing genes. Unlike traditional small molecules or biologics, ASOs work by binding to… Read More
A new on-demand webinar is now available from Taconic Biosciences. Join geneticist Bart Smits PhD as he outlines key considerations for designing and maintaining a robust mouse colony to support your preclinical research needs. Dr Bart Smits currently leads the Department of Genetic Sciences and Compliance at Taconic… Read More
Join geneticist Bart Smits, PhD in this exclusive webinar as he outlines key considerations for designing and maintaining a robust mouse colony to support your preclinical research needs. Secure your spot to: Understand the impact of background strain and substrain on mutation expression. Explore effective… Read More
Vesper Bio has initiated a Phase Ib/IIa Proof of Concept (POC) study of its lead candidate VES001 for frontotemporal dementia. The SORT-IN-2 study will evaluate VES001 in patients with mutations in their progranulin-coding gene (GRN), which are causal for FTD(GRN). FTD(GRN) is an early onset degenerative brain disease which is… Read More
This is the latest episode of the free DDW narrated podcast, titled “New ways of looking at effective cancer treatment”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “3D Genomics and targeted cancer therapies”, “Democratising… Read More
Researchers have uncovered that a molecule used to increase the efficiency of CRISPR-Cas9 gene editing destroys parts of the genome. The team discovered that while AZD 7648 does improve efficiency, it has the unwanted side effect of destroying other areas of the genome. They argue that alternatives… Read More
